Last reviewed 2026-04-20 · How we verify

Nerventra (LAQUINIMOD)

Nerventra works by modulating the immune system to reduce inflammation in the central nervous system.

Nerventra (LAQUINIMOD) is a small molecule laquinimod developed by Teva, currently approved for the treatment of relapsing-remitting multiple sclerosis. Its exact target is unknown, but it is believed to modulate the immune system to reduce inflammation. Nerventra is a patented medication, and its commercial status is not off-patent. Key safety considerations include potential liver enzyme elevations and infections. Further research is needed to fully understand its pharmacokinetic properties.

At a glance

Mechanism of action

Think of Nerventra like a referee in a football game. The referee (Nerventra) steps in to prevent the opposing teams (the immune system and the central nervous system) from colliding and causing damage. By reducing inflammation, Nerventra helps to prevent the damage that can lead to multiple sclerosis symptoms.

Approved indications

• Relapsing remitting multiple sclerosis

Common side effects

No common side effects on file.

Key clinical trials

• Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (PHASE1)
• A Study of Laquinimod Eye-drops in Healthy Participants (PHASE1)
• A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis (PHASE2)
• BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (PHASE3)
• A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (PHASE2)
• A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis (PHASE2)
• A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course (PHASE3)
• A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.